We report here a rare case of hepatotoxicity induced by trastuzumab used for adjuvant therapy of human epidermal growth factor receptor type 2 (HER2)-positive breast cancer and we also include a brief literature review. This evidence concerns the gene ERBB2 and breast carcinoma.